论文部分内容阅读
目的:检测胰腺癌组织三结构域蛋白14(TRIM14)的表达，分析TRIM14表达水平与胰腺癌临床病理特征和预后关系，探讨其在肿瘤发生发展中的作用机制。方法:收集2016年1月至2018年12月间海军军医大学附属长海医院胰腺外科行手术切除且病理确诊的胰腺癌组织及对应的癌旁组织共176例，采用免疫组织化学染色检测胰腺癌及癌旁组织TRIM14蛋白表达，蛋白质印迹法检测癌组织TRIM14、磷酸化p65(P-p65)表达，荧光定量PCR法检测癌组织NF-κB靶基因Bcl-xl、CCND1、血管内皮细胞生长因子-C(VEGF-C) mRNA表达。分析TRIM14表达与肿瘤临床病理参数的相关性，采用Cox回归模型进行单因素和多因素分析TRIM14表达水平与胰腺癌患者无瘤生存期和总生存期的关系；分析TRIM14表达水平与NF-κB信号通路活化的内在联系。结果:胰腺癌组织TRIM14阳性表达率显著高于癌旁组织[86.93%(153/176)比27.27%(48/176)]，差异有统计学意义(n P<0.05)；TRIM14表达水平与胰腺癌患者的肿瘤临床分期、淋巴结转移和浸润深度显著相关(n P值分别为0.000、0.000、0.021)，而与患者性别、年龄及肿瘤分化程度、远处转移无明显相关性。Cox回归分析结果显示，TRIMI14蛋白的表达水平为影响胰腺癌患者无瘤生存期(n RR＝1.706，95% n CI 1.237～2.429，n P＝0.029)和总生存期(n RR＝1.806，95% n CI 1.984～2.831，n P＝0.029)的独立危险因素。胰腺癌组织TRIM14与P-p65的表达变化高度相关(n r＝0.86，n P<0.01)，与Bcl-xl、CCND1、VEGF-C mRNA的表达水平也高度相关(n r值分别为0.85、0.91、0.92，n P值均<0.01)。n 结论:TRIM14在胰腺癌组织高表达，是判断胰腺癌患者预后的重要指标。TRIM14可能通过激活NF-κB通路参与胰腺癌发生及恶性进展过程。“,”Objective:To investigate the expression of tripartite motif 14 (TRIM14) in human pancreatic cancer and analyze its relationship with clinicopathological features and prognosis, and further explore its functional mechanism in the development and progression of pancreatic cancer.Methods:176 pairs of pancreatic cancer tissues and corresponding adjacent tissues resected by surgery in Changhai Hospital affiliated with Navy Medical University from January 2016 to December 2018 were collected. The protein expression of TRIM14 in pancreatic cancer and adjacent normal tissue was detected by immunohistochemical staining. TRIM14 and phosphorylated p65 expression in pancreatic cancer was measured by western blotting. NF-κB targeting gene Bcl-xl, CCND1, VEGF-C mRNA was tested by real time quantitative PCR. The correlation between TRIM14 expression and clinicopathological characteristics was analyzed. The relationship between TRIM14 expression and tumor-free survival and overall survival of pancreatic cancer patients was evaluated by univariate and multivariate Cox regression model. The internal relationship between TRIM14 expression and the activation of NF-κB signaling pathway was analyzed.Results:The positive TRIM14 expression rate in pancreatic cancer was obviously higher than that in adjacent normal tissue [86.93%(153/176) n vs 27.27%(48/176)], and the difference was statistically significant (n P<0.05). The expression level of TRIM14 was correlated with the clinical stage, lymph node metastasis and invasion depth of pancreatic cancer (n P=0.000, 0.000, 0.021), but not obviously with gender, age, differentiation degree and distant metastasis. Cox regression analysis showed that the expression level of TRIM14 was the independent risk factor for tumor-free survival (n RR=1.706, 95%n CI 1.237-2.429, n P=0.029) and overall survival (n RR=1.806, 95% n CI 1.984-2.831, n P=0.029). The expression level of TRIM14 was tightly associated with the phosphorylation level of p65 (n R=0.86, n P<0.01), and the mRNA expression of Bcl-xl, CCND1 and VEGF-C was highly correlated with TRIM14 expression (n R=0.85-0.92, n P<0.01).n Conclusions:TRIM14 was highly expressed in pancreatic cancer tissues and was an independent risk factor for prognosis of pancreatic cancer patients. TRIM14 participates in the development and malignant progression of pancreatic cancer potentially n via activating NF-κB pathway.n